ReviewPharmaceutical research1998
DNA methylation as a target for drug design.
Review in Pharmaceutical research, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 79 citations in OpenAlex.
- DNMT3A in cancer: from epigenetic writer to oncogenic driver.Clinical epigenetics · 2026Review
- The evaluation of chitosan hydrogel based curcumin effect on DNMT1, DNMT3A, DNMT3B, MEG3, HOTAIR gene expression in glioblastoma cell line.Molecular biology reports · 2023Article
- Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy.The New England journal of medicine · 2022Article
- 5-Aza-2'-deoxycytidine induces a greater inflammatory change, at the molecular levels, in normoxic than hypoxic tumor microenvironment.Molecular biology reports · 2021Article
- Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia.Cancer drug resistance (Alhambra, Calif.) · 2021Article
- Non-epigenetic induction of HEXIM1 by DNMT1 inhibitors and functional relevance.Scientific reports · 2020Article
- Single-Center Experience With Epigenetic Treatment for Juvenile Myelomonocytic Leukemia.Frontiers in oncology · 2020Article
- Comprehensive and integrative analysis identifiesAnnals of translational medicine · 2019Article
- Methionine Synthase Reductase-A66G and -C524T Single Nucleotide Polymorphisms and Prostate Cancer: A Case-Control TrialAsian Pacific journal of cancer prevention : APJCP · 2019Article
- A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers.Clinical epigenetics · 2016Review
- Inhibition of Methicillin-resistant Staphylococcus aureus-induced cytokines mRNA production in human bone marrow derived mesenchymal stem cells by 1,25-dihydroxyvitamin D3.BMC cell biology · 2014Article
- Melatonin in the regulation of liver steatosis following prenatal glucocorticoid exposure.BioMed research international · 2014Article
- Myogenic-induced mesenchymal stem cells are capable of modulating the immune response by regulatory T cells.Journal of tissue engineering · 2014Article
- DNA methylation changes in a human cell model of breast cancer progression.Mutation research · 2010Article
- Protein methyltransferases as a target class for drug discovery.Nature reviews. Drug discovery · 2009Review
- Inhibition ofGastroenterology research · 2008Article
- DNA and the chromosome - varied targets for chemotherapy.Cell & chromosome · 2004Article
- Review
- AdoMet-dependent methylation, DNA methyltransferases and base flipping.Nucleic acids research · 2001Review
- Recent advances in molecular biological techniques and their relevance to pulmonary research.Thorax · 2000Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
DNA methylation is essential for normal embryonic development. Distinctive genomic methylation patterns must be formed and maintained with high fidelity to ensure the inactivities of specific promoters during development. The mutagenic and epigenetic aspects of DNA methylation are especially interesting because they may lead to the inactivation of genes which are involved in human carcinogenesis. The mutagenicity of 5-Methylcytosine (5mC) and the role of promoter hypermethylation in gene silencing, particularly in cancer, suggest a clinical significance for the design of novel DNA methylation inhibitors which may be utilized to reverse the effects of DNA methylation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.